BioMarin Pharmaceutical, Inc. (BMRN)
65.07
-1.63
(-2.44%)
USD |
NASDAQ |
Aug 24, 16:00
65.04
-0.04
(-0.05%)
After-Hours: 20:00
BioMarin Pharmaceutical Enterprise Value : 15.94B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 15.94B |
| August 21, 2026 | 16.25B |
| August 20, 2026 | 16.44B |
| August 19, 2026 | 16.76B |
| August 18, 2026 | 16.31B |
| August 17, 2026 | 16.24B |
| August 14, 2026 | 16.38B |
| August 13, 2026 | 16.61B |
| August 12, 2026 | 16.94B |
| August 11, 2026 | 16.80B |
| August 10, 2026 | 16.67B |
| August 07, 2026 | 15.69B |
| August 06, 2026 | 15.24B |
| August 05, 2026 | 14.94B |
| August 04, 2026 | 15.10B |
| August 03, 2026 | 14.95B |
| July 31, 2026 | 14.96B |
| July 30, 2026 | 15.07B |
| July 29, 2026 | 15.22B |
| July 28, 2026 | 15.36B |
| July 27, 2026 | 15.01B |
| July 24, 2026 | 14.83B |
| July 23, 2026 | 14.74B |
| July 22, 2026 | 14.65B |
| July 21, 2026 | 14.80B |
| Date | Value |
|---|---|
| July 20, 2026 | 14.78B |
| July 17, 2026 | 14.88B |
| July 16, 2026 | 14.96B |
| July 15, 2026 | 14.75B |
| July 14, 2026 | 14.69B |
| July 13, 2026 | 14.80B |
| July 10, 2026 | 14.79B |
| July 09, 2026 | 14.95B |
| July 08, 2026 | 14.91B |
| July 07, 2026 | 15.02B |
| July 06, 2026 | 14.72B |
| July 02, 2026 | 14.76B |
| July 01, 2026 | 14.53B |
| June 30, 2026 | 14.42B |
| June 29, 2026 | 10.37B |
| June 26, 2026 | 10.63B |
| June 25, 2026 | 10.31B |
| June 24, 2026 | 10.30B |
| June 23, 2026 | 10.14B |
| June 22, 2026 | 10.03B |
| June 18, 2026 | 9.794B |
| June 17, 2026 | 9.857B |
| June 16, 2026 | 9.877B |
| June 15, 2026 | 9.979B |
| June 12, 2026 | 10.04B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Incyte Corp. | 21.22B |
| Alnylam Pharmaceuticals, Inc. | 31.24B |
| Vertex Pharmaceuticals, Inc. | 132.85B |
| Ionis Pharmaceuticals, Inc. | 10.41B |
| Regeneron Pharmaceuticals, Inc. | 80.37B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 44.76M |
| Revenue (Quarterly) | 996.38M |
| Total Expenses (Quarterly) | 951.62M |
| EPS Diluted (Quarterly) | 0.2302 |
| Gross Profit Margin (Quarterly) | 72.27% |
| Profit Margin (Quarterly) | 4.49% |
| Earnings Yield | 0.57% |
| Operating Earnings Yield | 5.06% |
| Normalized Earnings Yield | 3.027 |